Zacks Research Has Optimistic Outlook of CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a note issued to investors on Wednesday, January 29th. Zacks Research analyst K. Das now expects that the biotechnology company will earn $0.29 per share for the quarter, up from their previous forecast of $0.27. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q1 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.75 EPS and FY2026 earnings at $2.53 EPS.

CORT has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Finally, Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $66.92 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The company has a 50-day moving average of $56.02 and a 200-day moving average of $47.00. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $71.29. The company has a market capitalization of $7.01 billion, a price-to-earnings ratio of 53.11 and a beta of 0.56.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. During the same period last year, the business earned $0.28 earnings per share. Corcept Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in shares of Corcept Therapeutics during the third quarter valued at $25,000. Kestra Investment Management LLC bought a new stake in Corcept Therapeutics during the 4th quarter worth about $27,000. Kathleen S. Wright Associates Inc. acquired a new position in Corcept Therapeutics during the 3rd quarter valued at about $36,000. USA Financial Formulas bought a new position in shares of Corcept Therapeutics in the 4th quarter valued at about $54,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Corcept Therapeutics during the 4th quarter worth approximately $58,000. 93.61% of the stock is currently owned by institutional investors.

Insider Transactions at Corcept Therapeutics

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.88, for a total transaction of $131,736.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William Guyer sold 3,394 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $48.97, for a total transaction of $166,204.18. Following the completion of the transaction, the insider now owns 5,796 shares of the company’s stock, valued at $283,830.12. This trade represents a 36.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,405 shares of company stock valued at $1,627,772 in the last three months. 20.50% of the stock is owned by corporate insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.